• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?

作者信息

Elverdi Tuğrul, Özer Çerme Melis Dila, Aydın Tahacan, Eşkazan Ahmet Emre

机构信息

Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

Department of Internal Medicine, Cerrahpaşa Faculty of Medicine,Istanbul University-Cerrahpaşa, Fatih,Istanbul,Turkey.

出版信息

Expert Rev Clin Pharmacol. 2021 Oct;14(10):1183-1188. doi: 10.1080/17512433.2021.1944102. Epub 2021 Jul 9.

DOI:10.1080/17512433.2021.1944102
PMID:34130583
Abstract
摘要

相似文献

1
Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?接受卡泊单抗治疗的免疫介导性血栓性血小板减少性紫癜患者需要抗血栓治疗吗？
Expert Rev Clin Pharmacol. 2021 Oct;14(10):1183-1188. doi: 10.1080/17512433.2021.1944102. Epub 2021 Jul 9.
2
Caplacizumab: frequent local skin reactions.卡泊单抗：频繁出现局部皮肤反应。
Ann Hematol. 2021 Dec;100(12):3051-3052. doi: 10.1007/s00277-020-04260-7. Epub 2020 Sep 30.
3
Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜的临床药理学。
Expert Rev Clin Pharmacol. 2019 Jun;12(6):537-545. doi: 10.1080/17512433.2019.1607293. Epub 2019 Apr 28.
4
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).卡泊珠单抗治疗获得性血栓性血小板减少性紫癜（大力神试验）。
Transfus Med. 2019 Jun;29(3):146-148. doi: 10.1111/tme.12615.
5
Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura.卡普拉珠单抗在获得性血栓性血小板减少性紫癜治疗中的作用。
J Oncol Pharm Pract. 2020 Oct;26(7):1695-1702. doi: 10.1177/1078155220934862. Epub 2020 Jun 30.
6
Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.基于模型的卡普西珠单抗剂量推荐用于儿童获得性血栓性血小板减少性紫癜。
J Clin Pharmacol. 2022 Mar;62(3):409-421. doi: 10.1002/jcph.1991. Epub 2021 Nov 29.
7
Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab.一名血栓性血小板减少性紫癜患者在接受卡泊单抗治疗期间血小板计数正常时发生致命性脑出血。
Platelets. 2022 Apr 3;33(3):484-485. doi: 10.1080/09537104.2021.1922883. Epub 2021 May 12.
8
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.卡普雷珠单抗可降低获得性血栓性血小板减少性紫癜患者的主要血栓栓塞事件、恶化事件和死亡的发生频率。
J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.
9
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.卡泊西单抗作为获得性血栓性血小板减少性紫癜的一种新兴治疗选择。
Drug Des Devel Ther. 2019 Apr 17;13:1251-1258. doi: 10.2147/DDDT.S134470. eCollection 2019.
10
Caplacizumab treatment for acquired refractory thrombotic thrombocytopenic purpura.卡泊西单抗治疗获得性难治性血栓性血小板减少性紫癜。
Br J Haematol. 2020 Oct;191(2):e44-e46. doi: 10.1111/bjh.16977. Epub 2020 Aug 1.

引用本文的文献

1
Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues.免疫性血栓性血小板减少性紫癜：病理生理学、诊断、治疗及未解决的问题。
Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024060. doi: 10.4084/MJHID.2024.060. eCollection 2024.
2
Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta-analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura.卡泊单抗用于治疗血栓性血小板减少性紫癜会增加复发、病情加重和出血的风险吗？基于血栓性血小板减少性紫癜国际工作组修订标准的最新系统评价和荟萃分析。
EJHaem. 2023 Dec 18;5(1):178-190. doi: 10.1002/jha2.833. eCollection 2024 Feb.
3
Cardiovascular Disease and Stroke in Immune TTP-Challenges and Opportunities.免疫性血栓性血小板减少性紫癜中的心血管疾病与中风：挑战与机遇
J Clin Med. 2023 Sep 14;12(18):5961. doi: 10.3390/jcm12185961.
4
The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome.利伐沙班联合替格瑞洛在非瓣膜性心房颤动合并急性冠状动脉综合征患者PCI术后抗栓治疗中的价值
Evid Based Complement Alternat Med. 2022 Nov 3;2022:4807175. doi: 10.1155/2022/4807175. eCollection 2022.
5
Diagnosis and treatment of thrombotic microangiopathy.血栓性微血管病的诊断与治疗。
Int J Lab Hematol. 2022 Sep;44 Suppl 1(Suppl 1):101-113. doi: 10.1111/ijlh.13954.